Evidence Hub

Synthesis of glibenclamide cocrystals through grinding methods

Inês Gonçalves Pêcego

Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT), 2018

Abstract

The pharmaceutical industry has been struggling against problems related with drugs with low solubility as this is a very limiting factor in the development of drug products. Co-crystals are solid forms known for a very long time although they have not been fully explored in their potentialities. Co-crystals can be defined as crystalline homogenous structures composed of two or more compounds, held together by noncovalent bonds, usually hydrogen bonds, and solid at room temperature. These structures can change the physicochemical properties of drugs, like solubility, dissolution rate, stability and particle properties, which could be interesting for the drug development process. It is still difficult to identify the optimal co-crystallization method for each situation and typically this process is evaluated on a case-by-case basis. Reported studies show that the most commonly used method is solvent evaporation. However, the main drawback of solvent evaporation is the scale-up difficulty. Therefore, this work explored milling as an alternative method. This method can more easily be scaled-up. This work is based on the co-crystallization of glibenclamide, a sulfonylurea used in the treatment of non-insulin-dependent diabetes mellitus. Glibenclamide is categorized as a class II drug (low solubility, high permeability) by the Biopharmaceutical Classification System. The formation of co-crystals was attempted with six different co-formers – adenine (ADE), nicotinamide (NICO),…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free